UroMems Receives Clearance from the FDA and the French ANSM for Initiating Landmark Pivotal Clinical Study of UroActive® Smart Implant to Treat Male Stress Urinary Incontinence

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

UroMems-Clearance

More Like This

PR Newswire associated0

UroMems Reaches Significant Milestone: Successful Results in Clinical Feasibility Study of UroActive™ Smart Implant for Stress Urinary Incontinence Treatment

PR Newswire associated0

UroMems Raises Record $47 million (€44 Million) in Series C Financing to Fund Pivotal Clinical Trials of the UroActive™ System, the First Smart Automated Implant to Treat Stress Urinary Incontinence

PR Newswire associated0

UroMems Announces Successful Results in First-Ever Female Clinical Feasibility Study of UroActive® Smart Implant for Stress Urinary Incontinence Treatment

PR Newswire associated0

UroMems Announces Results of First-Ever Smart Artificial Urinary Sphincter Implant in Female Patient to Treat Stress Urinary Incontinence

UroMems Welcomes Medical Device Technology Leader Dan Rose as New Board Chairman

PR Newswire associated0

UroMems Appoints Former Axonics Executive Rinda Sama to Board of Directors

PR Newswire associated0

Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome

PR Newswire associated0

Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA™ (vibegron) in overactive bladder.